Bank Of New York Mellon Corp Aravive, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.93 - $1.9 $40,616 - $82,980	-43,674 Reduced 74.25%	15,144 $15,000
Q2 2021 Aug 11, 2021	BUY	$4.65 - $6.42 $75,474 - $104,203	16,231 Added 38.11%	58,818 $0
Q1 2021 May 13, 2021	SELL	$5.11 - $9.24 $7,629 - $13,795	-1,493 Reduced 3.39%	42,587 $0
Q4 2020 Feb 09, 2021	SELL	$4.36 - $6.51 $5,149 - $7,688	-1,181 Reduced 2.61%	44,080 $0
Q3 2020 Nov 12, 2020	BUY	$4.7 - $12.06 $9 - $24	2 Added 0.0%	45,261 $0
Q2 2020 Aug 12, 2020	BUY	$5.18 - $14.81 $165,532 - $473,268	31,956 Added 240.22%	45,259 $0
Q1 2020 May 06, 2020	SELL	$3.5 - $13.77 $497 - $1,955	-142 Reduced 1.06%	13,303 $0
Q1 2019 May 14, 2019	BUY	$3.35 - $8.27 $45,040 - $111,190	13,445 New	13,445 $95,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.